Primary Biliary Cholangitis (PBC) is a chronic liver disease caused by the destruction of the bile ducts in the liver. It is a type of autoimmune disorder, in which the body's immune system mistakenly attacks healthy cells and tissues. Treatment for PBC includes medications to reduce inflammation, slow the progression of the disease, and improve liver function.
The PBC drug market is a subset of the larger liver and kidney disorders drugs market. It includes medications that are used to treat PBC, such as ursodeoxycholic acid (UDCA), obeticholic acid (OCA), and elafibranor. These drugs are used to reduce inflammation, slow the progression of the disease, and improve liver function. In addition, there are other drugs used to treat the symptoms of PBC, such as antidiarrheal medications, antispasmodics, and antacids.
The companies in the PBC drug market include AbbVie, Allergan, Gilead Sciences, Intercept Pharmaceuticals, Merck, and Novartis. Show Less Read more